INNOVIMMUNE
  • Home
  • About Us Management
  • Pipeline INV-17 ROR Gamma Inverse Agonist INV-88 MIF Inhibitor INV-71 ROR Gamma Agonist INV-25 LXR Agonist INV-33 FXR Agonist
  • Media
  • Contact Us
INNOVIMMUNE
  • Home/
  • About us/
    • About Us
    • Management
  • Pipeline/
    • Pipeline
    • INV-17 ROR Gamma Inverse Agonist
    • INV-88 MIF Inhibitor
    • INV-71 ROR Gamma Agonist
    • INV-25 LXR Agonist
    • INV-33 FXR Agonist
  • Media/
  • Contact Us/
iStock_61826284_LARGE.jpg
INNOVIMMUNE

BIOTHERAPEUTICS

Media

INNOVIMMUNE
  • Home/
  • About us/
    • About Us
    • Management
  • Pipeline/
    • Pipeline
    • INV-17 ROR Gamma Inverse Agonist
    • INV-88 MIF Inhibitor
    • INV-71 ROR Gamma Agonist
    • INV-25 LXR Agonist
    • INV-33 FXR Agonist
  • Media/
  • Contact Us/
February 17, 2015

INV-17 ROR gamma Autoimmune Disease Preclinical POC

February 17, 2015/ Innovimmune Media

INV-17 preclinical findings of its Autoimmune Disease portfolio profiled in BioCentury Week in Review

Read More +

February 17, 2015/ Innovimmune Media/

Innovimmune Media

  • INV-17 ROR gamma inhibitor ...
  • Superior treatment efficacy of ...
  • Home/
  • About us/
    • About Us
    • Management
  • Pipeline/
    • Pipeline
    • INV-17 ROR Gamma Inverse Agonist
    • INV-88 MIF Inhibitor
    • INV-71 ROR Gamma Agonist
    • INV-25 LXR Agonist
    • INV-33 FXR Agonist
  • Media/
  • Contact Us/

INNOVIMMUNE

Media

Featured
Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego
Feb 28, 2018
Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego
Feb 28, 2018
Feb 28, 2018
Sep 14, 2017
Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland
Sep 14, 2017
Sep 14, 2017
Mar 5, 2017
Psoriasis treatment efficacy of an Oral INV-17 ROR gamma inhibitor in a mouse Imiquimod Psoriasis model presented at the 2017 AAD Annual Meeting in Orlando, FL
Mar 5, 2017
Mar 5, 2017
Efficacy of INV-17 ROR gamma inhibitor in a mouse Lupus model highlighted at the EULAR 2015 meeting in Rome, Italy
Jun 11, 2015
Efficacy of INV-17 ROR gamma inhibitor in a mouse Lupus model highlighted at the EULAR 2015 meeting in Rome, Italy
Jun 11, 2015
Jun 11, 2015
INV-17 ROR gamma inhibitor portfolio in preclinical development stage
May 15, 2015
INV-17 ROR gamma inhibitor portfolio in preclinical development stage
May 15, 2015
May 15, 2015
INV-17 ROR gamma Autoimmune Disease Preclinical POC
Feb 17, 2015
INV-17 ROR gamma Autoimmune Disease Preclinical POC
Feb 17, 2015
Feb 17, 2015
Superior treatment efficacy of novel oral DMARDs: INV-17 ROR gamma & INV-88 MIF inhibitors in murine CIA to be presented at the 2014 ACR Annual Meeting in Boston
Nov 5, 2014
Superior treatment efficacy of novel oral DMARDs: INV-17 ROR gamma & INV-88 MIF inhibitors in murine CIA to be presented at the 2014 ACR Annual Meeting in Boston
Nov 5, 2014
Nov 5, 2014
Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its proprietary oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases
Jul 25, 2014
Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its proprietary oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases
Jul 25, 2014
Jul 25, 2014
Innovimmune INV-17 ROR gamma inhibitor prevents Multiple Sclerosis in mice
Jan 21, 2014
Innovimmune INV-17 ROR gamma inhibitor prevents Multiple Sclerosis in mice
Jan 21, 2014
Jan 21, 2014
Innovimmune: Structuring Immunotherapies
Oct 1, 2012
Innovimmune: Structuring Immunotherapies
Oct 1, 2012
Oct 1, 2012